Addicted to proteostasis: How KRAS-driven cancers acquire resistance to clinical KRAS inhibitors
- PMID: 37977128
- DOI: 10.1016/j.chembiol.2023.10.007
Addicted to proteostasis: How KRAS-driven cancers acquire resistance to clinical KRAS inhibitors
Abstract
The development of KRAS inhibitors was a remarkable feat, yet their efficacy is limited by inevitable resistance. In the September issue of Science, Lv et al.1 demonstrate how KRAS-driven cancers rewire signaling to restore protein homeostasis and acquire resistance to KRAS inhibitors with implications for novel combination therapeutic strategies.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no competing interests.
Comment on
-
Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors.Science. 2023 Sep 8;381(6662):eabn4180. doi: 10.1126/science.abn4180. Epub 2023 Sep 8. Science. 2023. PMID: 37676964 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
